Stay updated on Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.
Latest updates to the Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check11 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant revision.SummaryDifference0.3%
- Check18 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check48 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference3%
- Check62 days agoChange DetectedNew features have been added to the website, while several options related to participant groups, interventions, and data download formats have been removed.SummaryDifference4%
- Check69 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference4%
Stay in the know with updates to Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib vs Lapatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.